<DOC>
	<DOCNO>NCT02004106</DOCNO>
	<brief_summary>This open-label , multi-center , dose-escalation study evaluate safety , pharmacokinetics , therapeutic activity RO6895882 participant Carcinoembryonic Antigen ( CEA ) -positive solid tumor progress standard care therapy . The study conduct 3 part . Part 1 single ascend dose study single participant cohort low RO6895882 dose ( less equal [ &lt; /= ] 6 milligram [ mg ] ) . Part 2 dose-escalation study RO6895882 monotherapy give every week ( qw ) , every 2 week ( q2w ) , possibly every 3 week ( q3w ) . Part 3 expansion phase qw , q2w , possibly q3w maximum tolerate dose ( MTD ) ( determine Part 2 ) . Part 3 conduct risk/benefit assessment , evaluate Sponsor investigator , favor participant . Participants treat disease progression , unacceptable toxicity withdrawal treatment reason death maximum duration 24 month .</brief_summary>
	<brief_title>A Study Evaluate Safety , Pharmacokinetics , Efficacy RO6895882 Participants With Advanced and/or Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Participants confirm advanced and/or metastatic solid tumor , least one tumor lesion noncritical location accessible biopsy progress standard care therapy Locally confirm CEA expression tumor tissue ( [ &gt; ] 20 percent ( % ) tumor cell stain least moderate intensity ) centrally confirm CEA expression archival tumor tissue fresh biopsy collect Radiologically measurable clinically evaluable disease Life expectancy great equal ( &gt; /= ) 12 week Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 01 All acute toxic effect prior radiotherapy , chemotherapy surgical procedure must resolve Grade &lt; /=1 , except alopecia ( grade ) Grade 2 peripheral neuropathy Adequate hematological , liver , renal function Negative serum pregnancy test within 7 day prior study treatment premenopausal woman woman &lt; /=2 year menopause Participants Gilbert 's syndrome eligible study . A diagnosis Gilbert 's syndrome base exclusion disease base follow criterion : ( ) unconjugated hyperbilirubinemia note several occasion ; ( ii ) evidence hemolysis ( normal hemoglobin , reticulocyte count , Lactate dehydrogenase ) ; ( iii ) normal liver function test ; ( iv ) absence disease associate unconjugated hyperbilirubinemia History clinical evidence central nervous system ( CNS ) primary tumor metastases include leptomeningeal metastasis unless previously treat , asymptomatic requirement steroid enzyme induce anticonvulsant last 14 day screen Participants active second malignancy ( nonmelanoma skin cancer , cervical carcinoma situ ) . Participants history malignancy consider active malignancy complete therapy consider treat physician le ( &lt; ) 30 % risk relapse Evidence significant , uncontrolled concomitant disease could affect compliance protocol interpretation result , include diabetes mellitus , history relevant pulmonary disorder know autoimmune disease Uncontrolled hypertension ( systolic &gt; 150 millimeter mercury [ mmHg ] and/or diastolic &gt; 100 mmHg ) , unstable angina , congestive heart failure ( CHF ) New York Heart Association ( NYHA ) classification , serious cardiac arrhythmia require treatment ( exception : atrial fibrillation , paroxysmal supraventricular tachycardia ) , history myocardial infarction within 6 month enrollment Active uncontrolled infection Known infection human immunodeficiency virus ( HIV ) , seropositive status Positive test result chronic hepatitis B infection ( define positive Hepatitis B surface antigen [ HBsAg ] serology and/or HBcAb status ) Positive test result hepatitis C ( hepatitis C virus [ HCV ] antibody serology test ) Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition would contraindicate use investigational drug Pregnant breastfeeding woman Known hypersensitivity component RO6895882 Concurrent therapy investigational drug Regular immunosuppressive therapy ( , organ transplantation , chronic rheumatologic disease ) Chronic use steroid ( include inhale ) allow . Concurrent high dos systemic corticosteroid . High dose consider &gt; 20 mg dexamethasone day ( equivalent ) &gt; 7 consecutive day Radiotherapy within last 4 week start study drug treatment exception limit field palliative radiotherapy bone pain relief</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>